Breathe Easier: Cancer R&D Innovation Puts Strong Focus on the Lung
IMS Health
Innovation in oncology continues to dominate the drug development pipeline, with accelerated approvals, increased funding and awareness, and an overall pipeline of almost 2,000 active products under study accounting for one-third of all pharmaceutical R&D. However, while many oncology indications are experiencing success in life extension with overall five-year survival rates at more than 66%, others such as lung cancer are struggling to achieve the same results, with a mere 16.8% of patients achieving five-year survival. While these rates may be low, innovation in lung cancer is at an all-time high; extending survival of lung cancer patients has become a large industry investment.
However, an interesting finding is that the U.S. has remained cost neutral over the last five years in R&D cost per-patient spend, in addition to remaining visit neutral in the area of lung cancer research (see chart). Ex-U.S. has experienced the opposite—with a correlation between increased patient visits and increased per-patient spend. What is fueling this increase in activity? Is this purely a result of globalization of research over the past five years? Or perhaps the U.S. has become more efficient in execution, thus controlling spend, but with little new outcomes. — IMS Health
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
